drugset
drugset / Trial / NCT06126861

The Mass Balance Study of LP-168 in Healthy Subjects

NCT06126861 ↗

Phase 1 Completed 6 enrolled Guangzhou Lupeng Pharmaceutical Company LTD.
NaSingle-groupOpen-labelTreatment

Summary

This study is a single-center, open-label, single-dose clinical pharmacokinetic study. The purpose of this study is to investigate the absorption characteristics, as well as to evaluate the metabolism and elimination pathways after a single oral dose of 150mg, 100μCi \[14C\]LP-168 in healthy subjects.

Timeline

Start
2023-12-25
Primary completion
2024-02-02
Completion
2024-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Rocbrutinib Small molecule 150 mg Oral

Indications

No indication recorded.